Course: Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples
CME Credits: 1.00
Released: 2021-07-21
Vaccination with 2 doses of the BNT162b2 vaccine (Pfizer-BioNTech) reportedly provides 95% protection from COVID-19. However, patient age is known to contribute to the risk of COVID-19 incidence and severity. We examined the relationship between age and neutralizing antibody titers against the early SARS-CoV-2 USA-WA1/2020 strain and the P.1 variant of concern after 2 doses of the BNT162b2 vaccine.
Educational Objective
To identify the key insights or developments described in this article
View Full Course